Artery Research

Volume 20, Issue C, December 2017, Pages 61 - 61

5.6 LONGITUDINAL FOLLOW-UP OF ARTERIAL STIFFNESS IN PATIENTS WITH SEVERE PSORIASIS TREATED BY ANTI-IL12/IL-23 COMPARED TO ANTI-TNF ALPHA

Authors
Hakim Khettab1, Manuelle Viguier2, Idir Hamdidouche3, Hervé Bachelez1, Pierre Boutouyrie4, 1, 3
1Assistance Publique Hôpitaux de Paris, France
2CHU Reims, France
3INSERM U970, France
4Université Paris Descartes, France
Available Online 6 December 2017.
DOI
10.1016/j.artres.2017.10.052How to use a DOI?
Abstract

Patients with chronic severe psoriasis are at increased cardiovascular risk (CVR). Modern systemic treatments of psoriasis involve anti-TNF alpha (ATNF) and more recently introduced anti-IL12/IL-23 (ustekinumab, AIL12/23) which, by interfering with IL-17, a possibly vasculoprotective cytokine, may increase CVR. We characterized large arteries remodeling and stiffness during longitudinal follow-up under ATNF and AIL12/23.

We included 31 patients. Followed-up was 13 ± 3 months with a mean number of 3 visits. Patients were treated either by ATNF (n = 13) or by AIL12/23 (n = 18). Mean age was 49 (27–71) 50% were females, 89% were overweight, 55% smokers and 32% (well controlled) hypertensives. Patients did not differ for severity scores of psoriasis or baseline characteristics. Carotid to femoral pulse wave velocity (PWV) and central pressure (applanation tonometry), carotid PWV and IMT (echotracking) were measured at each visit.

Blood pressure and heart rate did not change with either treatment. Carotid diameter did not change during follow-up, IMT increased more with AIL12/23 than in ATNF group (diff. à 18 months 75 μm, p = 0.10). Carotid distension and carotid distensibility decreased significantly under AIL12/23, whereas it increased with ATNF, independently of BP. Carotid PWV and CF-PWV increased independently of BP with AIL12-23 and decreased with ATNF (18 months diff. +1.60 m/s and +1.15 m/s, p < 0.05, respectively).

We documented an increased in stiffness and hypertrophy of large arteries during longitudinal follow-up of patients under antiinterleukin 12/23 treatment for psoriasis, compared to antiTNFalpha. Whether this is due to a protective effect of ATNF and/or adverse effect of AIL12-23 remains to be determined.

Open Access
This is an open access article distributed under the CC BY-NC license.

Reference

1.H Bachelez, Interleukin 23 inhibitors for psoriasis: not just another number, Lancet, 2017, pp. 31474-5.
Journal
Artery Research
Volume-Issue
20 - C
Pages
61 - 61
Publication Date
2017/12/06
ISSN (Online)
1876-4401
ISSN (Print)
1872-9312
DOI
10.1016/j.artres.2017.10.052How to use a DOI?
Open Access
This is an open access article distributed under the CC BY-NC license.

Cite this article

TY  - JOUR
AU  - Hakim Khettab
AU  - Manuelle Viguier
AU  - Idir Hamdidouche
AU  - Hervé Bachelez
AU  - Pierre Boutouyrie
PY  - 2017
DA  - 2017/12/06
TI  - 5.6 LONGITUDINAL FOLLOW-UP OF ARTERIAL STIFFNESS IN PATIENTS WITH SEVERE PSORIASIS TREATED BY ANTI-IL12/IL-23 COMPARED TO ANTI-TNF ALPHA
JO  - Artery Research
SP  - 61
EP  - 61
VL  - 20
IS  - C
SN  - 1876-4401
UR  - https://doi.org/10.1016/j.artres.2017.10.052
DO  - 10.1016/j.artres.2017.10.052
ID  - Khettab2017
ER  -